骨硬化蛋白与骨质疏松:治疗的新方向

被引：7

作者：

张树东 ^{[1
]}

祝孟海 ^{[1
]}

李世飞 ^{[1
]}

姚琦 ^{[1
,2
]}

机构：

[1] 首都医科大学附属北京世纪坛医院

[2] 解放军总医院

来源：

中国组织工程研究 | 2017年 / 21卷 / 36期

关键词：

骨质疏松; 抗体,单克隆; 组织工程; 组织构建; 骨组织工程; 骨硬化蛋白; 骨硬化病; 骨硬化蛋白抗体; 生活方式; Wnt/β-cateninLRP5/6; Romosozumab; Blosozumab;

D O I：

暂无

中图分类号：

R580 [];

学科分类号：

摘要：

背景:骨硬化蛋白的研究为骨质疏松的治疗提供了一个新的方向,通过促进骨生成,抑制骨吸收改善骨质疏松。目的:系统梳理骨硬化蛋白与骨质疏松相关文献,为进一步研究和促进骨硬化蛋白应用于骨质疏松的临床治疗和预防提供理论支持,提高骨质疏松的诊断和治疗效果。方法:以"Osteoporosis,Sclerostin,Sclerosteosis,Wnt/β-catenin,LRP5/6,Sclerostin antibody,Sclerostin and life style,Romosozumab、Blosozumab"为英文检索词,检索Pub Med数据库相关文献,经过筛选对其中的58篇文献进行分析探讨。结果与结论:(1)骨硬化蛋白的缺失或合成减少能促进骨的生成,骨硬化蛋白抗体在动物实验和临床试验中表现良好,能很好的促进骨生成,抑制骨吸收;(2)临床Ⅲ期试验结果支持前期试验所表现出的骨硬化蛋白单克隆抗体在骨代谢中的双重作用,表现出较好的治疗骨质疏松的应用前景;(3)研究发现血清骨硬化蛋白水平与生活方式关系密切,具体的对应关系还需进一步的验证;(4)大量的实验结果支持骨硬化蛋白应用于临床,骨硬化蛋白的研究为骨质疏松的预防和治疗提供一个新的方向。

引用

页码：5847 / 5854

页数：8

共 21 条

[1]

Sclerostin's role in bone's adaptive response to mechanical loading.[J].Gabriel L Galea;Lance E Lanyon;Joanna S Price.Bone.2017,

[2]

Sclerostin Antibody Therapy for the Treatment of Osteoporosis: Clinical Prospects and Challenges.[J].Claire MacNabb;D. Patton;J. S. Hayes;Merry Jo Oursler.Journal of Osteoporosis.2016,

[3]

Wnt signaling in bone and muscle.[J].Michael A. Rudnicki;Bart O. Williams.Bone.2015,

[4]

The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density [J].

Recknor, Christopher P. ;

Recker, Robert R. ;

Benson, Charles T. ;

Robins, Deborah A. ;

Chiang, Alan Y. ;

Alam, Jahangir ;

Hu, Leijun ;

Matsumoto, Toshio ;

Sowa, Hideaki ;

Sloan, John H. ;

Konrad, Robert J. ;

Mitlak, Bruce H. ;

Sipos, Adrien A. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (09) :1717-1725

[5]

The Anti-Osteoanabolic Function of Sclerostin Is Blunted in Mice Carrying a High Bone Mass Mutation of Lrp5 [J].

Yorgan, Timur A. ;

Peters, Stephanie ;

Jeschke, Anke ;

Benisch, Peggy ;

Jakob, Franz ;

Amling, Michael ;

Schinke, Thorsten .

JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (07) :1175-1183

[6]

A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density [J].

Recker, Robert R. ;

Benson, Charles T. ;

Matsumoto, Toshio ;

Bolognese, Michael A. ;

Robins, Deborah A. ;

Alam, Jahangir ;

Chiang, Alan Y. ;

Hu, Leijun ;

Krege, John H. ;

Sowa, Hideaki ;

Mitlak, Bruce H. ;

Myers, Stephen L. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2015, 30 (02) :216-224

[7]

A Review of Osteocyte Function and the Emerging Importance of Sclerostin [J].

Compton, Jocelyn T. ;

Lee, Francis Y. .

JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 2014, 96A (19) :1659-1668

[8]

Expression of Sclerostin scFv and the Effect of Sclerostin scFv on Healing of Osteoporotic Femur Fracture in Rats [J].

Yao, Qi ;

Ni, Jie ;

Hou, Yu ;

Ding, Lixiang ;

Zhang, Licheng ;

Jiang, Hua .

CELL BIOCHEMISTRY AND BIOPHYSICS, 2014, 69 (02) :229-235

[9]

Single-and Multiple-Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women [J].

McColm, Juliet ;

Hu, Leijun ;

Womack, Theresa ;

Tang, Cheng Cai ;

Chiang, Alan Y. .

JOURNAL OF BONE AND MINERAL RESEARCH, 2014, 29 (04) :935-943

[10]

Reversing LRP 5 ‐Dependent Osteoporosis and SOST Deficiency–Induced Sclerosing Bone Disorders by Altering WNT Signaling Activity.[J].Ming‐Kang Chang;Ina Kramer;Hansjoerg Keller;Jonathan H Gooi;Corinne Collett;David Jenkins;Seth A Ettenberg;Feng Cong;Christine Halleux;Michaela Kneissel.J Bone Miner Res.2014, 1

← 1 2 3 →